The Monsters She Faced and the Woman She Found: Author Angie Lickliter Shares Her Journey of Healing and Hope in ‘Finding Her'
In her debut memoir, Finding Her, Angie Lickliter shares the raw, unfiltered story of her journey through chronic illness, self-doubt, and healing. Diagnosed with Crohn's disease at the age of 27, she has spent decades navigating a battlefield of physical pain, emotional isolation, and inner chaos. Her story is not one of overnight transformation, but of deep work, relentless self-discovery, and finally, self-acceptance.
'I didn't just write Finding Her, I lived it,' says Lickliter. 'Page by page, I faced the monsters that once defined me: shame, heartbreak, the battle with my body, and the silence of not feeling enough. This book is my victory. It's a message to every woman that healing is possible. You can rise. You can rewrite your story. And you can find her, because she's still in there.'
Published on June 2 by Landon Hail Press, Finding Her quickly rose to become the #6 New Release in Women's Personal Growth and a Top New Release in Women's Spiritual Growth. It also ranked #2 in New Releases for Family & Personal Growth. Book cover design by Rich Johnson of Spectacle Photography, with photography by Angelli Nguyen and creative direction by Samantha Joy.
Finding Her is more than a memoir; it's a roadmap for anyone who has ever felt broken, invisible, or unsure of where to turn next. Through raw storytelling and deep honesty, Angie offers her readers a gripping account of her personal battles with the inner 'monsters' that once threatened to define her.
Designed to lead readers through Angie's journey from start to finish, Finding Her gives readers a firsthand account of the encounters with her monsters, who all represent a fear or shame Angie felt at one point in time. Along the way, the readers also meet the author's 'allies', who are unexpected people, practices, and moments of clarity that helped her survive. The book concludes with an empowering collection of 'weapons' – or tools – like meditation, yoga, journaling, and more, that helped Angie become stronger and more self-aware after every battle.
This book was written to empower you, the reader, to face your own monsters with courage and clarity. While everyone's monsters are different, they all whisper doubts, reinforce patterns, and keep you stuck in shadows. Angie's story, with the tools that she provides, proves that with the right support and inner work, healing isn't just possible, it's inevitable.
'Angie's bravery to shed the monsters that once shaped her identity is the permission every woman needs to overcome a false sense of self,' says Samantha Joy, Editor-in-Chief at Landon Hail Press. ' Finding Her encourages you to embark on the journey back to who you were before the world told you who to be.'
Author Angie Lickliter shines beautifully as she is photographed by Angelli Nguyen. Creative direction by Samantha Joy.
For over 25 years, Angie has lived with Crohn's disease, which has greatly influenced her own personal battles with food, alcohol, and toxic relationships. Angie brings both vulnerability and wisdom to the pages of her memoir. Her work as a certified holistic wellness and cannabis coach, along with her leadership of countless support groups, fuels her mission to empower women to reclaim their health, identity, and power.
This summer, Finding Her dares women to slow down, look inward, and ask the bigger questions in order to discover their true selves.
'I wrote Finding Her to tell my story,' Angie says. 'I built Finding Her to help you rewrite yours.'
Dedicated to creating a sacred and transparent space for writers, Landon Hail Press allows authors to own the creative direction of their book and their brand. LHP books have been sold on Amazon, Barnes & Noble, bookshop.org, and more, and featured in major publications like People.com.
Are you an aspiring author? Book a free consultation with Landon Hail Press here.
For further information, please contact: dottie@rebeccacafiero.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
2 days ago
- Associated Press
How to Carrie On: A New Web Series on Activism, Midlife, and the Power of Storytelling
Created by Carrie Murray, the new series explores what it means to amplify voices, navigate darkness, and use story as a catalyst for social change LOS ANGELES, CA / ACCESS Newswire / July 31, 2025 / In a time of uncertainty, storytelling becomes a lifeline. It connects us to not only the truth, but to each other. It gives us hope in a time when the world feels heavy and uncertain. Inspired by the legacy of those who spoke out when silence was easier, Carrie On! With Carrie Murray explores how personal narrative can spark collective action. For Carrie Murray, what started off as dinner parties with fellow frustrated entrepreneurs quickly turned into a thriving network of women committed to rewriting the rules of business and life. After a decade of connecting thousands of women in business and stimulating over $ 2.5 million in funding through the Bra Network, Carrie is turning the spotlight on a new project: Carrie On. Carrie's new web series invites intergenerational conversations that span career, identity, resilience, and liberation. She's not asking for a seat at the table; she's setting her own. As the host and creator of Carrie On!, a bold web series and podcast that hands the mic to voices rich with unfiltered wisdom, wit, rage, reinvention, and joy, Carrie makes sure that Carrie On! doesn't just tell stories, but that it reminds us we're not alone. The show is made for anyone on the edge of transformation: Gen Xers in their reinvention era, millennials holding it all together, and even younger listeners who've been forced to grow up fast. Maya WashingtonF. Michael Young Carrie On! is a movement. Produced by Rolling Water Entertainment, LLC in partnership with BRA Media under the BRA Network, Carrie On! amplifies the voices of women who refuse to be ignored. Born from Carrie's disappointment by the complacency of some women, yet deeply inspired and energized by those who are rising up, Carrie On! is Carrie's way of bringing together two of her greatest passions: fearless entrepreneurship and bold, disruptive women sharing their truths. This is a space for women 40+ to have the tough, necessary conversations and shine a light on what we need right now. The 2024 election made one thing painfully clear: marginalized voices are under attack. Government policies are muting dissent, and without relentless advocacy, our democracy and fundamental rights are at risk. Carrie On! is a stand, a space for women to show up, speak out, share their talents, and get unapologetically real. Because they refuse to be muted. Kathy Schuh Carrie Murray is a founder, speaker, author, and unapologetic amplifier of those often pushed to the edges. She is the founder of BRA - Business Relationship Alliance - a community built to connect and elevate female and non-binary entrepreneurs through visibility, collaboration, and real, lasting support. With a background in social justice, education, and entrepreneurship, Carrie brings a lived understanding of what it means to build something meaningful while balancing real life. She was the first in her family to graduate from college, later becoming a teacher, school principal, and founder of a school for twice-exceptional students. Her leap into entrepreneurship was born out of necessity, curiosity, and community, and she's been building bridges for others ever since. In a culture that's constantly telling women to shrink, Carrie On! invites you to expand. This is the show for those done being defined by what they lack and ready to be seen for what they are: brilliant, brave, and fully here. Tracy O'Malley For further information, please contact: [email protected] SOURCE: Carrie Murray LLC press release
Indianapolis Star
5 days ago
- Indianapolis Star
GEN and Sulfateq BV Announce Positive Phase 1 Trial Data on Investigational Drug SUL-238 for Alzheimer's and Other Neurodegenerative Diseases
Phase 1 results demonstrate that SUL-238, a first-in-class, orally administered, mitochondria-directed drug candidate, is safe and well-tolerated in healthy elderly volunteers, showing a favourable pharmacokinetic profile and high brain penetration. These findings support the advancement of SUL-238 into further clinical development for Alzheimer's and other neurodegenerative diseases. ANKARA, TR / ACCESS Newswire / July 28, 2025 / GEN Pharmaceuticals ( Türkiye's leading specialty pharmaceutical company, announced positive results from its Phase 1 clinical trial evaluating the safety, tolerability, and pharmacokinetics (PK) of first-in-class and novel orally administered mitochondria-directed drug candidate SUL-238 in healthy elderly volunteers. The findings were presented at the Alzheimer's Association International Conference 2025 (AAIC ®) in Toronto. This single oral ascending dose (SAD) Phase 1, first-in-human, randomized, double-blind, placebo-controlled study was conducted in three parts, involving a total of 53 healthy elderly adults. Part 1 included 6 cohorts (50, 100, 250, 500, 1000, and 2000 mg orally, n=23). In Part 2, the PK of a single 1000 mg oral dose was investigated in 10 healthy elderly adults. In Part 2B, the food effect was assessed using a randomized, single oral 2000 mg dose, two-treatment, two-period, crossover design (n=20). The trial results showed that single oral doses of 50-2000 mg of SUL-238 were safe and well-tolerated, while demonstrating a favourable PK profile and high cerebrospinal fluid (CSF) penetration. These findings make SUL-238 a promising candidate for further clinical development in neurodegenerative diseases, including Alzheimer's disease. No adverse effects (AEs) limited dose escalation, AE rates were comparable between SUL-238 and placebo, and all AEs were mild or moderate. The mean terminal elimination half-life was 0.86-3.80 hours, and the time to maximum plasma concentration was 0.50-1.39 hours. Under fed conditions, maximum plasma concentration (C max) and area under the plasma concentration-time curve (AUC 0-∞) decreased by 50% and 60%, respectively. CSF-to-plasma percentages at 2 and 8 hours post-dose were 21.1% (±6.6%) and 74.2% (±46.0%). Abidin Gülmüş, Chairman of GEN, stated: 'We are very encouraged by these promising first-in-human results, marking an important step forward in our mission to address the underlying biology of Alzheimer's disease.' Nadir Ulu, MD, PhD, Vice President of R&D at GEN, added: 'With its excellent safety and PK profile in this Phase 1 trial, combined with robust preclinical data, SUL-238 represents a strong candidate for further clinical development to meet the critical unmet needs in neurodegenerative diseases, including Alzheimer's disease.' About SUL-238 SUL-238 is a novel, first-in-class, hibernation-derived small molecule that targets mitochondria, the cell's 'powerhouse.' It supports mitochondrial bioenergetics via complex I/IV activation and has improved mitochondrial function in rodent models of neurodegenerative, cardiovascular, and renal diseases, as well as aging. SUL-238 crosses the blood-brain barrier and has undergone extensive safety evaluation in preclinical and Phase 1 studies. GEN licenses SUL-238 from Sulfateq BV for neurodegenerative disease applications. About GEN: Founded in 1998, GEN is Türkiye's leading specialty pharmaceutical company, focused on developing innovative therapies across multiple therapeutic areas. GEN manufactures high-quality, competitive products at its GMP-certified facility and pursues original drug development through two dedicated R&D centers and investments. About Sulfateq: Sulfateq B.V. is an early-stage Dutch biotech company that fosters strategic collaborations with academic and industrial research centers to accelerate the development of innovative new medicines. It has developed a novel class of small molecules, the SUL-compounds, that maintain mitochondrial health. Contact Information Bulutay Güneş Sr. Head of Corporate Brand Ali Ketencioğlu Investor Relations Manager Kees van der Graaf Sulfateq CEO View the original press release on ACCESS Newswire The post GEN and Sulfateq BV Announce Positive Phase 1 Trial Data on Investigational Drug SUL-238 for Alzheimer's and Other Neurodegenerative Diseases appeared first on DA80 Hub.
Associated Press
25-07-2025
- Associated Press
Primus Sounds Alarm on Chronic Venous Insufficiency as President Trump's Diagnosis Sparks National Focus
SCOTTSDALE, ARIZONA / ACCESS Newswire / July 24, 2025 / Following reports of President Donald J. Trump's diagnosis with Chronic Venous Insufficiency (CVI), Primus Pharmaceuticals, Inc. strongly calls on healthcare providers to intensify efforts to diagnose and treat this silent epidemic affecting 25-30 million Americans because only less than <10% are actually treated. Leg swelling, heaviness, and varicose veins are often dismissed as cosmetic or 'normal aging,' while they can signal a dangerous progression toward severe complications including thromboembolism (blood clots), debilitating pain, non-healing leg ulcers, and compromised mobility. Widespread, Under-Recognized Health Threat Life-Changing Solution: Vasculera® Primus offers Vasculera, the only U.S. prescription product for CVI. It is specifically formulated as a medical food for the clinical dietary management of CVI. Taken once daily, this 600mg tablet delivers highly purified, bioavailable diosmin, a flavonoid sourced from oranges, in combination with a pH buffering agent and: Manufactured in the U.S., Vasculera presents a novel naturally-derived alternative to the status quo. Expert Physician Perspectives 'CVI and its manifestation in skin known as stasis dermatitis is a very common condition that can lead to significant impairment and morbidity,' said Dr. Mark Nestor, MD, PhD, Board-certified Dermatologist and Voluntary Professor, Department of Dermatology and Cutaneous Surgery, University of Miami, Miller School of Medicine. 'Diosmin in its bioavailable form in the pharmaceutical-grade medical food Vasculera is a natural flavonoid that has scientifically proven benefit for this condition.' Board-certified Vascular Surgeon Dr. Ron Bush, MD, FACS, one of the world's foremost experts in the histology and treatment of venous disease states, 'CVI is a common condition, with symptoms that may vary but are consistently linked to elevated venous pressure. In my clinical experience, Vasculera has proven to be an effective treatment option. Its active ingredient, diosmin, is well-studied and widely documented for its ability to address the inflammation associated with chronic venous hypertension. Vasculera is also well-tolerated and has no significant contraindications.' Robust Clinical Backing Public Health Call to Action With an aging population and more time on electronic devices fueling CVI's prevalence, Primus urges clinicians to: For prescribing information, visit About Primus Pharmaceuticals Primus innovates in prescription nutritional therapies targeting metabolic causes of chronic diseases across rheumatology, dermatology, and women's health. We develop and commercialize first-in-class products and novel deliveries in Rx drugs, medical foods, and medical devices to fill key unmet needs with universal patient access not provided by traditional pharma. Visit Contact InformationRandy Keating Public Relations Manager 4802460509 SOURCE: Primus Pharmaceuticals press release
